Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Avutometinib and Defactinib in RAF Dimer-Driven Thyroid Cancer
NCT06007924Phase 2Recruiting
- Sponsor
- Memorial Sloan Kettering Cancer Center
- Start
- Aug 2023
- Primary completion
- Aug 2027
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label trial of avutometinib and defactinib in thyroid cancer (2 cohorts), sponsored by Memorial Sloan Kettering Cancer Center. Primary endpoint: Overall Response Rate up to 2 years. Started Aug 2023; status: recruiting.
02
Drugs
avutometinibdefactinib
03
Conditions
thyroid cancer
Beyond the preview
Go deeper on NCT06007924.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06007924.